Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Unresectable or Metastatic Melanoma

Background: Lifileucel is a tumor-derived autologous T-cell therapy approved by the US FDA for the treatment of patients with advanced (unresectable or metastatic) melanoma previously treated with an immune checkpoint inhibitor and, if BRAF V600-mutated, a BRAF ± MEK inhibitor. The benefit of commercial lifileucel has not yet been investigated in a real-world clinical setting. We report the first multicenter experience of lifileucel in patients with advanced melanoma.